

CIBERONC

Ampliando fronteras dentro de CIBER

Jornada Científica CIBERESP

13 de junio - Madrid

Joaquín Arribas

Scientific Director of CIBERONC

CIBERONC mission: Promote stable collaborative translational cancer research in Spain, focusing on translational precision medicine as a strategy to meet the European priorities.



Gastro-Intestinal
Tumors



Breast Cancer




Respiratory Tract
Tumors



Hematological
Tumors



Low Prevalence
Tumors



Mechanisms of
Tumor Progression




Liquid biopsy & Biomarkers

Cancer Bioinformatics & Omics



Drug Resistance & New Therapies

Immuno-Oncology



Experimental Models

Training & Mobility

2017

Launching and Net Consolidation

- Internal Organization
- Programs Consolidations
- National Visibility

- Promote CIBERONC collaborative scientific activity
 - Intra & Inter-Program
 - InterCIBERs
 - With external entities

2020

Internationalization & Translation

- Results translation (tech transfer, clinical assays, spin-off)
- International visibility

Scientific Activity

Co-funded seed projects:

- 2018: CIBER-BBN
- 2019: CIBERES

I Foro de proyectos colaborativos CIBERONC – CIBER-BBN



CIBER-BBN / CIBERONC | miércoles, 18 de abril de 2018

Other activities:

Jornadas de Formación CIBERES

Encuentro para la excelencia CIBERESP

ciberonc **isciii**

Centro de Investigación Biomédica en Red
Cáncer

Buscar

QUIÉNES SOMOS ▾

GRUPOS ▾

PROGRAMAS DE INVESTIGACIÓN ▾

PROGRAMAS TRANSVERSALES ▾

SALA DE PRENSA ▾

» Convocatorias » Convocatoria de ayudas para asistir al "Encuentro para la Excelencia de la Investigación en Salud Pública"

Convocatoria de ayudas para asistir al "Encuentro para la Excelencia de la Investigación en Salud Pública"

Convocatoria de Ayudas para asistir al "Encuentro para la Excelencia de la Investigación en Salud Pública", **Escuela de Verano de Salud Pública Lazareto de Maó, Menorca, (19, 20 y 21 de septiembre de 2018).**

El Programa de Formación del CIBER en el área temática de Epidemiología y Salud Pública, en colaboración con las áreas de Obesidad y Fisiopatología de la Nutrición, Enfermedades Cardiovasculares y Cáncer, quiere propiciar el intercambio de ideas, en un ambiente informal, entre científicos acreditados y jóvenes científicos en formación, debatiendo sobre sus proyectos de Tesis Doctoral. Este intercambio no sólo pretende mejorar los proyectos, se trata también de facilitar la innovación en la investigación de salud pública y su incardinación en los retos de la salud del siglo XXI.

Entidad Financiadora: CIBERESP

Plazo de Presentación: 14/06/2018

Estado: Abierta

Documentación:

Convocatoria FECD Menorca CIBERESP 2018.pdf

CIBERONC

Research Programs



Gastro-Intestinal
Tumors



Breast Cancer




Respiratory Tract
Tumors



Hematological
Tumors



Low Prevalence
Tumors



Mechanisms of
Tumor Progression



Gabriel Capellá
IDIBELL (Barcelona)

Josep M. Tabernero. VHIO

Eduardo Díaz-Rubio. HCSC

Manel Esteller. IDIBELL

Eduard Batlle. IRB

Enrique Aranda. IMIBIC

Jaime Feliu. H La Paz

Alfredo Carrato. HU RyC

Núria Malats. CNIO

Francisco X. Real. CNIO

Andrés Cervantes. INCLIVA

Colorectal Cancer & Pancreatic Cancer

- 1** Molecular epidemiology of cancer (GWAS, moderate risk alleles or high-risk alleles) & correlation of main exposures.
- 2** Tumor cell genomic and transcriptomic classification.
- 3** Personalized in vitro / in vivo models for sequential treatments response.
- 4** Real time- dynamic liquid biopsy

Breast Cancer



Atanasio Pandiella
CIC (Salamanca)

Joan Albanell. IMIM

Ana Lluch. INCLIVA

Amparo Cano. IIB

José Palacios. HUVR

Joaquín Arribas. VHIO

Miguel Martín. HGM

1

Incorporation of translational studies to investigator initiated clinical trials (CDK inhibitors and T-DM1)

2

Development of the liquid biopsy (CTCs, tfDNA)

3

Dynamic evolution of breast cancer

Evaluation of pairs of primary tumors and metastases

- Primary tumors Vs metastases
- Comparison between gene expression and the mutational profile of residual tumor after neoadjuvant chemotherapy and the first metastatic relapse
- Genetic or/and epigenetic alterations of heterogeneity of TNBC.

4

Immune therapies. Generation of preclinical models

5

Novel therapies, drug resistance and mechanisms involved in the pathophysiology of breast cancer.

Respiratory Tract Tumors



Luis Montuenga
CIMA (Pamplona)

Luiz Paz-Ares. H120

Amancio Carnero. IBiS

Carlos Camps. HCV

Juan P. Rodrigo Tapia. FICYT

- 1** Identification and characterization of genomic aberrations (genomics, epigenomics and in silico analysis).
- 2** Preclinical evaluation of novel targeted therapy strategies against SCC: translational analysis of the survival relevance of specific genetic alterations.
- 3** Evaluation, validation of emerging immunotherapy approaches for SCC and prediction of efficacy and resistance based on tumor genomic profile and immune and microenvironmental landscape
- 4** In vitro and in vivo analysis of therapeutic combinations of immunotherapy based treatments
- 5** Biomarker analysis in liquid biopsies (screening, early diagnostics, and prediction or monitorization of therapeutic responses)

Hematological Tumors



Dolor Colomer
IDIBAPS (Barcelona)

Marcos Gonzalez. HUS

Elias Campo. IDIBAPS

Miguel A. Sanz. HU La Fe

Miguel A. Piris. HUMV

Jesús F. San Miguel. CIMA

José A. Orfao de Matos. HUS

José A. Pérez Simón. HUVR

Felipe Prósper. CIMA

- 1** Pathologic/immunophenotypic/molecular characterization. Accurate diagnosis and evaluation of potential biomarkers for prognostic and monitorization (Minimal Residual Disease (MRD))
- 2** Development of diagnostic tools applicable to clinical practice.
- 3** Development of pre-clinical models.
- 4** To promote clinical trials and controlled clinical assays.
- 5** Transversal aims: Development of clinical and biological databases to help/facilitate subsequent studies (epidemiological, clinical data, biomarkers...)

Low Prevalence Tumors



Enrique de Álava
IBiS (Sevilla)

Ignacio Melero. CIMA

Xavier Matías-Guiu. IRB

Rafael López López. ONCOMET

Santiago Ramón y Cajal. VHIR

Francesc X. Bosch. ICO

Rosa Noguera. INCLIVA

1

Prognostic and predictive biomarkers in sarcomas, carcinomas, melanomas and tumors of the nervous system.

2

Clinical relevance of exosomes, CTCs and ctDNA as reservoirs of metastatic markers and chemoresistance in sarcomas. Quantification and genomic characterization of the Tumor population circulating PD-L1 + and PD-L1-.

3

Tumor heterogeneity in endometrial cancer, sarcomas, melanomas and tumors of the nervous system using primary tissue, metastases and CTCs.

4

Search for predictive or monitoring biomarkers for the effectiveness of immunotherapy treatments

5

Multiplex tissue immunohistochemistry and immunofluorescence assays and automated multiparametric analysis for the study of immune, inflammatory and vascular cell infiltration in tumors

Mechanism of Tumor Progression



Xosé Bustelo
CIC (Salamanca)

Anna Bigas. IMIM

Jesús M. Paramio. CIEMAT

Carlos López Otín. UO

Alberto Muñoz Terol. IIB

María Pilar Santisteban. IIB

Eugenio Santos. CIC

Francisco J. Oliver. CSIC

Piero Crespo. IBBTEC

Arkaitz Carracedo. CIC BioGune

Joan Seoane. VHIO

- 1** Identification of early oncogenic drivers and signaling modifiers linked to tumor origin, progression, and therapeutic responsiveness (discovery phase)
- 2** Biological corroboration of candidate genes/programs as causal contributors to disease (validation phase)
- 3** Exploitation of candidate genes and pathways for precision medicine approaches (implementation phase)

CIBERONC

Transversal Programs



Liquid Biopsy & Biomarkers

Rodrigo Toledo

Vall d'Hebron Instituto de Oncología



Cancer Bioinformatics & Omics

Víctor Quesada


Universidad de Oviedo



Drug Resistance & New Therapies

Alberto Ocaña

Universidad de Castilla La Mancha



Immuno-Oncology

Pedro Berraondo

Centro de Investigación de Medicina Aplicada



Modelos Experimentales

Patricia Pérez-Galán

Instituto de Investigaciones Biomédicas August Pi i Sunyer



Amparo Cano
UAM (Madrid)

- 1** Mobility Program
 - Intramural
 - National
 - International
- 2** Training Program
 - Course organization
 - Course attendance
- 3** Initiation to Oncology Research Program
 - 10 Launching Fellowship (6 month)
- 4** Promotion to Young Researcher
 - CIBERONC Young Researchers Meeting (14 – Nov)